Gladstone Institutional Advisory LLC Acquires 128,748 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gladstone Institutional Advisory LLC raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 847.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 143,939 shares of the company’s stock after buying an additional 128,748 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Teva Pharmaceutical Industries were worth $2,594,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in shares of Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares in the last quarter. Maple Rock Capital Partners Inc. lifted its position in shares of Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after purchasing an additional 1,770,000 shares in the last quarter. Truist Financial Corp lifted its position in shares of Teva Pharmaceutical Industries by 7.0% during the second quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after purchasing an additional 254,483 shares in the last quarter. Iron Triangle Partners LP lifted its position in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after purchasing an additional 1,469,864 shares in the last quarter. Finally, Tri Locum Partners LP lifted its position in shares of Teva Pharmaceutical Industries by 15.1% during the second quarter. Tri Locum Partners LP now owns 2,550,307 shares of the company’s stock valued at $41,442,000 after purchasing an additional 334,119 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on TEVA shares. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $18.46 on Friday. The company has a 50 day moving average of $18.02 and a 200 day moving average of $16.92. The stock has a market cap of $20.91 billion, a P/E ratio of -47.32, a P/E/G ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 12 month low of $8.55 and a 12 month high of $19.08. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.